RVTY: Financial results · Other company developments

Item 2.02. Results of Operations and Financial Condition On November 3, 2026 , Revvity, Inc. (the “Company”) announced its financial results for the third quarter ended October 4, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01. Other Events Exhibit 99.2 to the Current Report on Form 8-K sets forth the unaudited pro forma condensed consolidated financial statements to present the pro forma financial position and results of operations of the Company and its Subsidiaries based upon historical financial information after giving effect to the probable sale of substantially all of the assets related to the Company’s Immunodiagnostics business in China (“China IDX”) pursuant to a definitive agreement signed on July 31, 2026. The agreement provides for the sale of China IDX for up to $200 million, subject to adjustments and satisfaction of conditions. Management believes it is probable the transaction will close by the end of 2027 and therefore has included the unaudited pro forma condensed consolidated financial statements herein. Cautionary Statement Concerning Forward-Looking Statements Certain statements made herein contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but